Core Viewpoint - The announcement from Huadong Medicine indicates that several of its products have been included in the new drug catalog released by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, which is expected to aid future market promotion without significant immediate impact on recent performance [1] Group 1: Product Inclusion - Huadong Medicine's subsidiary, China-US Huadong, has its Ustinumab injection adjusted to routine catalog management, with changes in payment scope [1] - The cooperative products, Senaparib capsules and Vutrisiran capsules, have been included in the negotiated drug list during the agreement period [1] - The drug Zevulonase injection has been included in the commercial insurance innovative drug catalog [1] Group 2: Future Implications - The new drug catalog will be implemented starting in 2026, suggesting a longer-term benefit for the company's market positioning [1] - The inclusion of these products is expected to facilitate future market promotion efforts [1]

Core Viewpoint - The announcement by Huadong Medicine indicates changes in the management of its products under the new national medical insurance directory, which may impact the company's revenue and market positioning [1] Group 1: Product Adjustments - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has had its Ustinumab injection liquid adjusted to regular directory management, with changes in the payment scope compared to the previous version of the drug directory [1] - The company's cooperative products, Senapali capsules and Pentanedioic acid linaclotide capsules, have been included in the negotiated drug section within the agreement period [1] - The drug Zewokaiolun injection liquid has been included in the commercial insurance innovative drug directory [1] Group 2: Other Products - Other products from the subsidiary that are already included in the national medical insurance directory have not experienced any changes in their directory status during this update [1]

Core Viewpoint - Huadong Medicine has entered into an exclusive commercialization agreement for the product Linarazepine with several partners, coinciding with the inclusion of this product in the new national medical insurance directory, indicating a significant advancement in the company's strategic positioning in the digestive disease sector [1][5]. Group 1: Product and Market Potential - Linarazepine is a new generation potassium-competitive acid blocker (P-CAB) developed for treating digestive system diseases, specifically gastroesophageal reflux disease (GERD), and has been approved for commercialization in China [2][3]. - The drug has shown rapid onset and prolonged acid suppression, with a half-life of 8.68 hours, making it a promising alternative to traditional proton pump inhibitors (PPIs) [3][4]. - The market potential for Linarazepine is underscored by the success of the first P-CAB drug, which achieved sales exceeding 5 billion yuan in 2024, validating the clinical value of this drug class [4]. Group 2: Strategic Developments - The inclusion of Linarazepine and other products in the 2025 national medical insurance directory enhances patient accessibility and is expected to significantly boost sales [5][6]. - Huadong Medicine's strategic focus on innovative therapies in the digestive field reflects its commitment to addressing unmet clinical needs and expanding its product portfolio [4][8]. - The company has a robust commercialization platform, which is expected to facilitate rapid market penetration for Linarazepine and strengthen its leading position in the digestive disease sector [6][8]. Group 3: Financial Performance and Growth - In the first three quarters of 2025, Huadong Medicine reported a 62% year-on-year increase in revenue from innovative pharmaceutical products, amounting to 1.675 billion yuan [6]. - The company has successfully established a comprehensive commercialization team to promote its products, including Linarazepine, across various regions in China [5][6]. - The ongoing development of over 90 pipeline projects positions Huadong Medicine among the top tier of the domestic pharmaceutical industry, providing a strong foundation for future growth [6][7].

证券代码：000963 证券简称：华东医药 公告编号：2025-110 华东医药股份有限公司 关于全资子公司产品及合作产品纳入国家医保及商保创新 药目录的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年12月07日，国家医保局、人力资源社会保障部发布【关于 印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商 业健康保险创新药品目录》（2025年）的通知（医保发〔2025〕33 号）】（以下简称新版药品目录、商保创新药目录），华东医药股份 有限公司（以下简称"公司"）部分产品及合作产品被纳入新版药品 目录及商保创新药目录。 公司全资子公司杭州中美华东制药有限公司（以下简称"中美华 东"）乌司奴单抗注射液调整至常规目录管理，支付范围较前一版药 品目录有所变动。公司合作产品塞纳帕利胶囊、戊二酸利那拉生酯胶 囊被纳入协议期内谈判药品部分，泽沃基奥仑赛注射液被纳入商保创 新药目录。 详细情况如下： 一、新纳入新版药品目录情况 | | 药品名称 | | 药 品 | | | 协议 有效 | | | --- | --- | --- | --- | - ...

Core Viewpoint - The company has successfully achieved the conditions for the third unlock period of its 2022 restricted stock incentive plan, allowing 77 eligible participants to unlock a total of 1.27512 million shares, representing 0.07% of the company's total share capital, with the unlock date set for December 10, 2025 [2][33]. Summary by Sections Incentive Plan Approval and Execution - The company held its 11th Board of Directors' fifth meeting on November 20, 2025, where it approved the achievement of the third unlock conditions for the 2022 restricted stock incentive plan [2][8]. - The initial approval process for the incentive plan included multiple meetings and independent opinions confirming its alignment with the company's long-term development [4][5]. Unlock Conditions and Share Details - The third unlock period for the restricted stock began on November 17, 2025, and allows for a 40% unlock of the initially granted shares [18][19]. - The total number of shares eligible for unlock is 1.27512 million, with 77 participants meeting the conditions [33]. Adjustments and Repurchases - The company has made adjustments to the incentive plan, including the repurchase of shares from participants who no longer qualify due to personal reasons or performance issues, totaling 9.78 million shares [19][20]. - The repurchase price for the shares has been adjusted based on the company's profit distribution plan, ensuring compliance with regulatory requirements [23][24]. Future Share Structure Changes - The company anticipates changes in its share structure following the unlock of restricted stocks, although the exact impact will be confirmed by the relevant regulatory bodies [35][36].

Core Viewpoint - Next week, a total of 38 stocks will be unlocked, with a combined market value of 39.63 billion yuan based on the latest closing prices [2]. Group 1: Stock Unlocking Details - Ningbo Yiyang will have 1.06 billion shares listed for circulation, primarily from the original shareholders' restricted shares, with an unlocking market value of 9.71 billion yuan [3]. - EVE Energy ranks second in unlocking market value, with 125 million shares to be unlocked, mainly from the placement of shares to targeted investors, totaling 8.62 billion yuan [3]. - In contrast, Longxun Co., Xinghao Pharmaceutical, and Yinlong Co. have relatively low unlocking pressure, with unlocking market values of less than 10 million yuan each [4]. Group 2: Unlocking Proportions - The stocks with the highest unlocking ratios include Ningbo Yiyang, Oke Technology, and Jingpin Special Equipment, all exceeding 50% [5]. Group 3: Institutional Attention - Eight stocks facing unlocking have garnered significant institutional attention, with over 30 institutions conducting research since the fourth quarter [7]. - Among these, Juhe Materials has a market value of 1.056 billion yuan facing unlocking, and has received research from 161 institutions. The company specializes in the research, production, and sales of fluorochemical products [8]. - Huadong Medicine has received research from 132 institutions and has begun exporting some of its pharmaceutical products internationally, while also expanding its medical aesthetics business globally [9]. Group 4: Stock Performance - Among the 38 stocks facing unlocking, the average stock price has decreased by 0.14% since December [8]. - Changying Tong has the highest price increase, with a cumulative rise of 9.94% in December, while Sanfu Xinke has the largest decline, with a cumulative drop of 12.37% [8].

来源：政知见 原标题：《省委书记和李书福、刘杰等座谈，现场有企业家分享了一则"趣事"》 据《浙江日报》消息，12月4日上午，浙江省委书记王浩在杭州主持召开企业家和专家学者座谈会，听 取对明年经济形势和经济工作的意见建议。 企业家有7人，来自不同行业，包括： 浙江吉利控股集团董事长李书福 网易集团副总裁刘杰 阿里巴巴集团天猫总裁刘博 舜宇光学科技（集团）有限公司总裁王文杰 华东医药股份有限公司董事长吕梁 思看科技（杭州）股份有限公司董事长兼总经理王江峰 现场画面显示，座谈会上，有10位企业家和专家学者代表先后发言。 浙江中国小商品城集团股份有限公司董事长陈德占 专家有3人，分别是： 浙江大学文科资深教授史晋川 浙江省咨询委副主任、秘书长孟刚 浙江省发展规划研究院院长李军 此次座谈，聚焦的是明年经济。 "明年是'十五五'规划的开局之年，是推动高质量发展建设共同富裕示范区取得决定性进展、率先呈现 基本实现社会主义现代化生动图景的重要之年，做好明年经济工作十分重要。"王浩说。 作为全国重要的经济大省，浙江的经济体量和发展动向备受关注。2024年，全省地区生产总值超过9万 亿元，增长5.5%。今年前三季度，浙江全省地区 ...

Group 1 - The Zhejiang Provincial Secretary Wang Hao hosted a meeting with entrepreneurs and experts to discuss the economic outlook and work for the upcoming year [1] - Notable attendees included leaders from various industries, such as Li Shufu from Geely Holding Group and Liu Bo from Alibaba Group [3] - The discussion highlighted the significance of artificial intelligence, with several companies recognized as emerging forces in the tech sector, referred to as the "Six Little Dragons" of Hangzhou [4] Group 2 - Zhejiang's economic strength has seen significant growth, with a GDP reaching 68,495 billion yuan in the first three quarters of this year, marking a year-on-year increase of 5.7% [6] - The province has maintained its position as the leader in the number of private enterprises in the national top 500 for 27 consecutive years [8] - The upcoming year is crucial for implementing the "14th Five-Year Plan," focusing on high-quality development and the establishment of a common prosperity demonstration zone [8]

Core Viewpoint - East China Pharmaceutical announced the achievement of the third unlock condition for its 2022 restricted stock incentive plan, allowing 77 individuals to unlock a total of 1.27512 million shares, which represents 0.07% of the company's total share capital, with the listing date set for December 10, 2025 [2] Summary by Relevant Sections - **Incentive Plan Details** - The company has fulfilled the third unlock condition of its 2022 restricted stock incentive plan [2] - A total of 77 individuals are eligible for the unlock [2] - The number of shares that can be unlocked is 1.27512 million [2] - **Impact on Share Capital** - The unlocked shares account for 0.07% of the company's total share capital [2] - The shares will be available for trading starting December 10, 2025 [2]

Group 1 - The company emphasizes the importance of its internationalization strategy [1] - The pharmaceutical industrial segment has already exported some formulation products to international markets [1] - The innovative drug business is focusing on strengthening independent research and development while actively exploring business development opportunities with global peers [1]